These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 30470604)
1. Combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as a treatment for recurrent epithelial ovarian cancer-National Cancer Institute experience. Fahim MI; Nassar OA; Mansour OM; Ali AM; Mahmoud AM; Allam RM; Kamal A J Egypt Natl Canc Inst; 2018 Dec; 30(4):139-141. PubMed ID: 30470604 [TBL] [Abstract][Full Text] [Related]
2. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829 [TBL] [Abstract][Full Text] [Related]
3. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845 [TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263 [TBL] [Abstract][Full Text] [Related]
6. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial. Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135 [No Abstract] [Full Text] [Related]
7. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202 [TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience. Königsrainer I; Horvath P; Struller F; Grischke EM; Wallwiener D; Königsrainer A; Beckert S Langenbecks Arch Surg; 2014 Jun; 399(5):589-94. PubMed ID: 24817542 [TBL] [Abstract][Full Text] [Related]
9. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312 [TBL] [Abstract][Full Text] [Related]
10. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer. Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612 [TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Bakrin N; Cotte E; Golfier F; Gilly FN; Freyer G; Helm W; Glehen O; Bereder JM Ann Surg Oncol; 2012 Dec; 19(13):4052-8. PubMed ID: 22825772 [TBL] [Abstract][Full Text] [Related]
12. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512 [TBL] [Abstract][Full Text] [Related]
13. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149 [TBL] [Abstract][Full Text] [Related]
14. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis. Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430 [TBL] [Abstract][Full Text] [Related]
15. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292 [TBL] [Abstract][Full Text] [Related]
16. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832 [TBL] [Abstract][Full Text] [Related]
17. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Cascales-Campos PA; Gil J; Gil E; Feliciangeli E; González-Gil A; Parrilla JJ; Parrilla P Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409 [TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254 [TBL] [Abstract][Full Text] [Related]
19. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244 [TBL] [Abstract][Full Text] [Related]
20. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]